J Virol 1995,69(6):3290–3298.PubMed 23. Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG: Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 1992,116(5):1273–1281.PubMedCrossRef Selleckchem VS-4718 24. Feldman SA, Audet S, Beeler JA: The fusion glycoprotein of human respiratory syncytial virus facilitates

virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 2000,74(14):6442–6447.PubMedCrossRef 25. Terao-Muto Y, Yoneda M, Seki T, Watanabe A, Tsukiyama-Kohara K, Fujita K, Kai C: Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines. Antiviral Res 2008,80(3):370–376.PubMedCrossRef 26. Compton T, Nowlin DM, Cooper NR: Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. ERK inhibitor Virology 1993,193(2):834–841.PubMedCrossRef 27. Hilgard P, Stockert R: Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 2000,32(5):1069–1077.PubMedCrossRef 28. Barth H, Schnober

EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF: Viral and cellular determinants of the hepatitis C virus BX-795 price envelope-heparan sulfate interaction. J Virol 2006,80(21):10579–10590.PubMedCrossRef 29. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R: Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006,80(11):5308–5320.PubMedCrossRef 30. Zhang YJ, Hatziioannou

T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD: Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 2002,76(12):6332–6343.PubMedCrossRef 31. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001,289(2):283–296.PubMedCrossRef 32. Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA: Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J Virol 2007,81(1):261–271.PubMedCrossRef 33. Lin LT, Gemcitabine order Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, Lin TC, Wang GH, Lin CC, Richardson CD: Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol 2011,85(9):4386–4398.PubMedCrossRef 34. Julander JG, Perry ST, Shresta S: Important advances in the field of anti-dengue virus research. Antivir Chem Chemother 2011,21(3):105–116.PubMedCrossRef 35. Prichard MN, Kern ER: The search for new therapies for human cytomegalovirus infections. Virus Res 2011,157(2):212–221.PubMedCrossRef 36.